# FDA recall D-0093-2022

> **MERCK SHARP & DOHME CORP** · Class I · drug recall initiated 2021-10-19.

## Product

Cubicin (daptomycin for injection), 500 mg per vial, Single-dose vial, Rx only. Manuf. for: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ 08889, USA. Manuf. by: Baxter Pharmaceuticals LLC., Bloomington, IN 47403, USA, NDC: 67919-011-01

## Reason for recall

Presence of Particulate Matter: Identified as Glass Particles

## Distribution

Nationwide within the United States

## Key facts

- **Recall number:** D-0093-2022
- **Recalling firm:** MERCK SHARP & DOHME CORP
- **Classification:** Class I
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2021-10-19
- **Report date:** 2021-11-10
- **Termination date:** 2023-07-25

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Whitehouse Station, NJ, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0093-2022

## Citation

> AI Analytics. FDA recall D-0093-2022. Retrieved 2026-07-20 from https://api.ai-analytics.org/recall/D-0093-2022. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*